Chronos Therapeutics company

Chronos Therapeutics’ drug development scheme focuses in two main areas:
- Repositioning FDA approved drugs.
- Screening, discovery and development of novel proprietary drug candidates.
Current Targets
- Diseases of Ageing: Osteoporosis, Cancer and Sarcopenia.
- Neurodegenerative Diseases: Parkinson’s Disease, Alzheimer’s Disease, ALS and Orphan Synucleopathies.
Chronos Therapeutics’ research is successfully advancing from pre-clinical stages of development for age-related disease treatments to clinical development.
Chronos' pioneering drug discovery and development platform the Chronoscreen has enabled the company to quickly gain proprietary positions in the regulation of cellular chronological lifespan.
Technology: NeuroTech
Industry: NeuroTech
Headquarters: Oxford, Oxfordshire, United Kingdom
Founded Date: 7-1
Employees Number: 11-50
Funding Status: M&A
Investors Number: 3
Total Funding: £8M
Last Funding Type: Venture - Series Unknown

Visit Website
Register and Claim Ownership